https://orcid.org/0000-0002-5842-8080
Abstract
Objective
We aimed to prospectively evaluate the visit adherence in mild to moderate psoriasis patients.
Methods
Plaque psoriasis patients aged 18 or above who were prescribed with a two-component formula ointment were eligible for the study. The patients were randomly assigned to group A or B, and received management with or without planned patient-doctor communication via a mobile platform. The outpatient visit was scheduled at week 2, 8, 16, 28, 48, and 52. Visit adherence was evaluated as the visit rate of the patients.
Results
Two hundred twenty-one patients were included. Generally, the visit adherence dropped over time during follow-up. The visit rates in group A were 5.2–15.7% through the 52 weeks, and similar rates were found in group B (7.5–17.0%, vs group A, P > 0.05). A negative binomial regression model showed that older age and higher BSA were correlated with more frequent visits.
Conclusion
The visit adherence of mild to moderate psoriasis patients was very low in China. Proactive inquiries of the doctors via the mobile platform failed to improve the visit adherence of the patients.
Key Message
Visit adherence of mild-to-moderate psoriasis patients was found to be very low regardless of proactive inquiries of the doctors in this mobile-based study.
Data Sharing Statement
The data that support the findings of this study are available on request from the corresponding author.
Statement of Ethics
The study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The study was approved by the Ethics Committee of Beijing Tsinghua Changgung Hospital. All patients have given written informed consent at the beginning of the study.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
QZ and KDA are employees of LEO Pharma. The authors report no other conflicts of interest in this work.